- Interim data from SEAPORT-1, a Phase 1 trial of INZ-701 in patients with end-stage kidney disease receiving hemodialysis, on track for fourth quarter of 2024 - - Interim data from ENERGY-1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for second half of 2024 - - Cash, cash equivalents, and short-term investments as of March 31, 2024, expected to fund operations into the fourth quarter of 2025 - BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Co ...

INZ-701药物研究 - INZ-701是一种重组Fc融合蛋白，是一种ENPP1酶替代疗法（ERT），用于治疗血管、软组织和骨骼罕见疾病[1] - INZ-701在临床研究中表现出潜力，可以预防病理性矿化和内膜增殖，这些病理过程可能导致ENPP1缺陷、ABCC6缺陷和钙化性病变等疾病的发生[1] - INZ-701在多项临床试验中表现出良好的耐受性，有利的安全性，并显著增加了PPi水平[1] INZ-701在ABCC6缺陷患者中的疗效数据 - INZ-701在ABCC6缺陷患者中展示了有利的安全性、免疫原性和临床结果数据[2] - INZ-701在ABCC6缺陷患者中的探索性临床和疗效数据显示出潜在的有益效果[3] - INZ-701在ABCC6缺陷患者中的视觉功能问卷（VFQ-25）分数表明在48周内保持和改善了视觉功能[5] INZ-701在ENPP1缺陷患者中的疗效数据 - INZ-701在ENPP1缺陷患者中展示了有利的安全性概况，无严重或严重的与INZ-701相关的不良事件[21] - INZ-701在ENPP1缺陷患者中的抗药物抗体（ADA）数据显示出低滴度的非中和性ADA[23] 公司背景介绍 - Inozyme Pharma是一家临床阶段的罕见病生物制药公司，致力于开发治疗影响血管、软组织和骨骼疾病的新型治疗药物[2] - 公司网站提供更多信息，请访问https://www.inozyme.com/或关注Inozyme的LinkedIn、X（以前是Twitter）和Facebook页面[4]

BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it granted stock options to three new employees to purchase shares of the Company's common stock, pursuant to the Company's 2023 Inducement Stock Incentive Plan, as inducement material to the new employees entering into employm ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ to _____________________ Commission File Number: 001-39397 INOZYME PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware ...

Exhibit 99.1 Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights – Topline data from ongoing Phase 1/2 trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency expected in early April – – Phase 1 trial of INZ-701 in end-stage kidney disease (ESKD) patients receiving hemodialysis (SEAPORT-1) now underway (NCT06283589), with topline data expected in Q4 2024 – – Launched global patient registry (PROPEL) in partnership with GACI Global to advance understanding ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ to _____________________ Commission File Number: 001-39397 INOZYME PHARMA, INC. (Exact name of registrant as specified in its charter) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ to _____________________ Commission File Number: 001-39397 INOZYME PHARMA, INC. (Exact name of registrant as specified in its charter) Dela ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ to _____________________ Commission File Number: 001-39397 INOZYME PHARMA, INC. (Exact name of registrant as specified in its charter) Del ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ to _____________________ Commission File Number: 001-39397 INOZYME PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware ...

| --- | --- | --- | --- | --- | --- | |----------------------------------------------------------------------------------------------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ı | | | | | | | Our Mission | | | | | | | Fulfill an unmet medical need with therapeutic breakthroughs in rare diseases of pathologic mineralization and intimal proliferation | | | | | | December 2022 Legal Di ...